New York State Common Retirement Fund raised its stake in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 194.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 170,039 shares of the company’s stock after buying an additional 112,263 shares during the period. New York State Common Retirement Fund owned approximately 0.42% of Pacira Pharmaceuticals worth $8,111,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. BT Investment Management Ltd acquired a new position in Pacira Pharmaceuticals during the 2nd quarter valued at about $597,000. Amalgamated Bank increased its stake in Pacira Pharmaceuticals by 12.7% during the 2nd quarter. Amalgamated Bank now owns 5,030 shares of the company’s stock valued at $240,000 after buying an additional 566 shares during the period. BlackRock Inc. increased its stake in Pacira Pharmaceuticals by 9.2% during the 2nd quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock valued at $165,914,000 after buying an additional 294,494 shares during the period. Nationwide Fund Advisors increased its stake in Pacira Pharmaceuticals by 18.9% during the 2nd quarter. Nationwide Fund Advisors now owns 66,800 shares of the company’s stock valued at $3,186,000 after buying an additional 10,610 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in Pacira Pharmaceuticals by 13.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 320,019 shares of the company’s stock valued at $15,286,000 after buying an additional 37,488 shares during the period.

Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) opened at 34.95 on Wednesday. Pacira Pharmaceuticals, Inc. has a one year low of $29.95 and a one year high of $58.95. The firm’s market capitalization is $1.41 billion. The firm has a 50 day moving average of $36.97 and a 200 day moving average of $43.10.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.06). The company had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative net margin of 23.36% and a negative return on equity of 12.44%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company earned $0.21 earnings per share. Equities analysts forecast that Pacira Pharmaceuticals, Inc. will post ($0.18) EPS for the current year.

Several equities analysts have commented on the stock. Cowen and Company reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, July 14th. Wedbush reaffirmed an “outperform” rating and issued a $87.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 19th. BidaskClub raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Royal Bank Of Canada set a $58.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, June 27th. Finally, ValuEngine raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $52.07.

In related news, Director Paul J. Hastings sold 1,044 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the completion of the sale, the director now directly owns 3,518 shares of the company’s stock, valued at approximately $127,175.70. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO David M. Stack sold 28,885 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.37, for a total value of $1,050,547.45. Following the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at $5,788,794.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,390 shares of company stock valued at $1,215,480. 6.60% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/11/pacira-pharmaceuticals-inc-pcrx-shares-bought-by-new-york-state-common-retirement-fund.html.

Pacira Pharmaceuticals Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.